SHANDONG, China, March 10, 2020 (GLOBE NEWSWIRE) -- SPO Global, Inc. (OTC Markets: SPOM) (the "Company"), is pleased to announce a partnership with QingDao Fuyutang Health Development Franchises Ltd. ("Fuyutang Franchise"). Mr. Fengyou Lu, the CEO of SPO Global Inc., and Ms. Jiemei Wang, the Chairman & CEO of Fuyutang Franchises have signed a partnership agreement to set up more than 100 clinics in multiple cities, to build a national wide Fuyutang Chinese Medicine Clinic Franchise in the next two years.
Gerpang Healthcare Group will cooperate with Fuyutang Franchises in Medical terminal services, focusing on technical support, Chinese-Western medical cooperation, physicians advance training, and third-party standardization services to create a standardized medical service management model.
In the past ten years, Gerpang Healthcare Group has established a professional service system in cell energy detection, low-frequency laser treatment, and intelligent rehabilitation.
Through the integration of resources and complementary advantages, Gerpang and Fuyutang Health Franchise will definitely create a unique professional brand in this field. Based on the tenet of "Inheriting the culture of Chinese medicine and integrating the advantages of Chinese and Western medicine". Gerpang will cooperate with Fuyutang Health Franchise and serve the world, truly bring the gospel to global patients.
About Qingdao Fuyutang Health Development Ltd.
Qingdao Fuyutang Health Development Ltd. is a Chinese Medicine Clinic Franchise, was established on the initiative of Mr. Fuyu Li, a master of Chinese medicine. Mr. Li has loved Chinese medicine since his childhood. After a few decades medical practice, he has many disciples, superb medical skills. Mr. Li led his disciples and established branches in Beijing, Jinan, Qingdao, Suzhou, Weifang. Mr. Li has unique insights in cancer treatment, stroke rehabilitation, reproductive medicine and intractable diseases.
About SPO Global
SPO Global Inc. (OTC Markets: SPOM) recently completed its merger with Gerpang Healthcare Group. (www.gerpanghealthcare.com). Its subsidiary, Shandong Gerpang Biotechnology Co., Ltd. is an innovative and technological private enterprise located in the pharmaceutical Valley Industrial Park of Jinan high tech Zone. Its main business scope includes biomedical R&D, medical information software development and sales, medical high-tech introduction, medical high-quality consumables production and sales, health care products, drugs, medical equipment consumables agency and sales.
Company Disclaimers: As a "penny stock" Company, within the meaning of federal and state securities law, SPO Global, Inc. may not avail itself of the Safe Harbor provisions as identified in the Private Securities Litigation Reform Act of 1995. However, SPO Global, Inc. provides the following disclaimer and warning to protect our shareholders, prospective investors and the public at large by alerting them to the risks and uncertainties involved with any investment, and the need to perform their own due diligence and assessment.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission.
Company Contact:
fengyoulu@gmail.com
Source: SPO Global Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
